» Articles » PMID: 28979338

Monetary Value of Quality-Adjusted Life Years (QALY) Among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP)

Overview
Publisher Brieflands
Specialty Pharmacology
Date 2017 Oct 6
PMID 28979338
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to estimate the monetary value of a QALY among patients with heart disease and to identify its determinants. A cross-sectional survey was conducted through face-to-face interview on 196 patients with cardiovascular disease from two heart hospitals in Tehran, Iran, to estimate the value of QALY using disaggregated and aggregated approaches. The EuroQol-5 Dimension (EQ-5D) questionnaire, Visual Analogue Scale (VAS), Time Trade-Off (TTO) and contingent valuation WTP techniques were employed, first to elicit patients' preferences and then, to estimate WTP for QALY. The association of patients' characteristics with WTP for QALY, was assessed through Heckman selection model. The Mean willingness to pay per QALY, estimated by the disaggregated approach ranged from 2,799 to 3599 US dollars. It is higher than the values, estimated from aggregated methods (USD 2,256 to 3,137). However, in both approaches, the values were less than one Gross Domestic Product (GDP) per capita of Iran. Significant variables were: Current health state, education, age, marital status, number of comorbidities, and household's cost group. Our results challenge two major issues: the first, is a policy challenge which concerns the WHO recommendation to use less than 3 GDP per capita as a cost-effectiveness threshold value. The second, is an analytical challenge related to patients with zero QALY gain. More scrutiny is suggested on the issue of how patients with full health state valuation should be dealt with and what arbitrary value could be included in the estimation value of QALY when the disaggregated approach used.

Citing Articles

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.

Nu Vu A, Van Hoang M, Lindholm L, Sahlen K, Nguyen C, Sun S PLoS One. 2024; 19(2):e0297450.

PMID: 38329955 PMC: 10852300. DOI: 10.1371/journal.pone.0297450.


Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.

Peng Q, Yin Y, Liang M, Zhao M, Shao T, Tang Y Cost Eff Resour Alloc. 2023; 21(1):80.

PMID: 37915053 PMC: 10621116. DOI: 10.1186/s12962-023-00487-z.


Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.

Huang L, Peng X, Sun L, Zhang D Cost Eff Resour Alloc. 2023; 21(1):37.

PMID: 37277820 PMC: 10243056. DOI: 10.1186/s12962-023-00442-y.


Determination of a cost-effectiveness threshold for cancer interventions in Iran.

Safari H, Poder T, Afshari S, Nahvijou A, Arab-Zozani M, Moradi N Front Oncol. 2022; 12:1039589.

PMID: 36578935 PMC: 9791211. DOI: 10.3389/fonc.2022.1039589.


Cost-effectiveness analysis of fractional flow reserve versus angiography among patients with coronary artery disease undergoing borderline coronary lesions treatment in Iran.

Keshavarz K, Rezaee R, Esmaili E, Mansouri R, Jafari A, Erami A Cost Eff Resour Alloc. 2022; 20(1):66.

PMID: 36482396 PMC: 9730590. DOI: 10.1186/s12962-022-00402-y.


References
1.
Gyrd-Hansen D, Kjaer T . Disentangling WTP per QALY data: different analytical approaches, different answers. Health Econ. 2011; 21(3):222-37. DOI: 10.1002/hec.1709. View

2.
Weinstein M, Torrance G, McGuire A . QALYs: the basics. Value Health. 2009; 12 Suppl 1:S5-9. DOI: 10.1111/j.1524-4733.2009.00515.x. View

3.
Stinnett A, Paltiel A . Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997; 17(4):483-9. DOI: 10.1177/0272989X9701700414. View

4.
Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J . The social value of a QALY: raising the bar or barring the raise?. BMC Health Serv Res. 2011; 11:8. PMC: 3023672. DOI: 10.1186/1472-6963-11-8. View

5.
Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View